Sera Prognostics

SERA

Market cap $90M

Sera Prognostics (SERA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks are HRB, SPWH, SERA, VEEV and WKHS.

Sera Prognostics, Inc. (SERA) Q4 2025 Earnings Call Transcript

Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.25 per share a year ago.

SALT LAKE CITY, March 18, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key 2025 and Recent Highlights: Data Generation Published Landmark PRIME Study Demonstrating PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications: In January 2026, the PRIME Study, a randomized controlled trial of 5,018 women, was published in PREGNANCY, the peer-reviewed journal of the Society for Maternal-Fetal Medicine.

SALT LAKE CITY, March 4, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report fourth quarter and fiscal year 2025 financial results on Wednesday March 18, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.

SALT LAKE CITY, Feb. 17, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 1:10 p.m. ET. Members of management will participate in a fireside chat, highlighting Sera's latest achievements.

Sera Prognostics (SERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this year SALT LAKE CITY , Nov. 24, 2025 /PRNewswire/ -- Sera Prognostics, Inc. , The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the findings of the Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study were accepted for publication in a peer-reviewed  journal. The PRIME study's abstract data was selected as a late-breaking abstract for podium presentation earlier this year at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting.

Sera Prognostics, Inc. ( SERA ) Q3 2025 Earnings Call November 13, 2025 5:00 PM EST Company Participants Jennifer Zibuda - Head of Investor Relations Evguenia Lindgardt - President, CEO & Director Austin Aerts - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen, Research Division Margarate Boeye - William Blair & Company L.L.C., Research Division Presentation Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review third quarter fiscal year 2025 results.